Global Stock News

Can MGRO Scale Its Biologicals?

Can MGRO Scale Its Biologicals?

Key Highlights

  • On 27 August 2026, MustGrow reported second-quarter 2026 results that showed the early, uneven nature of its commercialisation.
  • Sales of its TerraSante product were about $75,000, down sharply from about $313,000 a year earlier, while licensing Revenue contributed about $1.4 million, bringing total recognised revenue to roughly $1.475 million.
  • The swing to a small net profit was helped by about $1.4 million in licensing revenue, underscoring the current importance of licensing to the income statement.
  • On the positive side, year-to-date TerraSante sales up about 46% versus the full prior year suggest underlying Demand is growing, and the planned shift to ocean freight…

Source link

Share this article

Scroll to Top